Investor Type | Firm |
Type of Fund | Private Equity Fund |
Industries | HealthTech (& Fitness) • Medical Devices (& Hospital Services) |
Stages | Expansion, MBO/LBO |
Investing | United Kingdom • France • Spain • Switzerland • Netherlands • Belgium • Europe • Finland • Norway |
Investment Range | €30,000,000 - €60,000,000 |
Assets Under Management | €560,000,000 |
G Square Healthcare Private Equity LLP is a distinguished private equity firm that concentrates on the mid-market sector within the healthcare industry, managing assets worth approximately 560 million euros. Founded in 2008 and headquartered in the vibrant area of Mayfair, London, G Square has developed a reputation for strategic investments in high-growth potential companies, particularly in HealthTech, Medical Devices, Hospital Services, and related fields. They specialize in expansion capital, management buyout and leveraged buyout scenarios, showcasing an expertise that aligns with ventures requiring investments ranging from 30 million to 60 million euros. G Square's investment thesis is built around the pursuit of innovation in healthcare, leveraging deep specialized sector knowledge and entrepreneurial support to drive growth and create value proactively. They have a keen focus on four distinct healthcare segments: Medical Products including equipment and devices, Healthcare IT such as software, telehealth, and AI technologies, Healthcare Services including diagnostics and specialized clinics, and Services to the Pharma Industry through contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Their professional team, comprising 30 individuals from 17 different nationalities with a combined 300 years of relevant experience and the capability to communicate in 17 languages, is a testament to the firm's strong buy and build credentials and European focus with a global outreach. G Square emphasizes their robust track record, having completed 24 deals and achieved a significant number of portfolio add-ons, thereby reinforcing their position as a leading private equity investor in the healthcare space.